Riskpilot← Back to searchSign inGet full accessSALMO PHARMA AS
ASActiveOrg 916266081Dønnaveien 496, 8820 DønnaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20150 employees
Revenue 2024
NOK 10,6M
+25768% vs 2023
EBITDA margin
69.8%
+299% vs 2023
Equity ratio
96.1%
Financial strength
Net profit 2024
NOK 7,1M
+659% vs 2023
| Revenue | NOK 10,6M | +25768% |
| EBITDA | NOK 7,4M | +299% |
| Net profit | NOK 7,1M | +659% |
| Total assets | NOK 13,5M | -63% |
| Equity | NOK 12,9M | -50% |
| Employees | 0 | — |
Legal name
SALMO PHARMA AS
Org number
916266081
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19. november 2015
Share capital
NOK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utføre forsøk og utviklingsarbeid innen akvakultur for næringsliv, offentlig organ og andre. Medvirke til undervisning/opplæring, rådgivnings- og utviklingsarbeid innen akvakultur. Gjennom samarbeid med brukere, formidle informasjon om fou-resultat, og bidra til at disse blir tatt i bruk. Drive oppdrett av laks, ørret og eventuelt andra arter. Investeringer i og drift og utleie av eiendom og driftsmidler, samt investeringer i aksjer og andeler.
Address
Dønnaveien 496, 8820 Dønna
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 140 106 | 153 618 | 103 286 | 154 924 | 41 | 10 612 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | 0 | −104 | −99 | −5 480 | 30 754 | 35 059 | 29 031 | 27 860 | −3 720 | 7 403 |
| Depreciation & amort. | −0 | −0 | −5 | −65 | −0 | −0 | −0 | −49 | −57 | −57 |
| EBIT | 0 | −104 | −104 | −5 545 | 30 754 | 35 059 | 29 031 | 27 811 | −3 777 | 7 346 |
| Net financials | 0 | 0 | 0 | −140 | 33 | 393 | 135 | 335 | 1 198 | 1 354 |
| Profit before tax | 0 | −104 | −104 | −5 685 | 30 787 | 35 453 | 29 166 | 28 147 | −2 579 | 8 700 |
| Tax | −0 | −0 | −52 | −1 250 | 5 799 | 6 679 | 5 372 | 5 147 | −1 314 | 1 623 |
| Net profit | 0 | −104 | −51 | −4 436 | 24 987 | 28 774 | 23 794 | 23 000 | −1 265 | 7 077 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 20 | 130 | 3 055 | 44 929 | 127 636 | 97 919 | 86 750 | 58 343 | 36 483 | 13 461 |
| Equity | 20 | 2 | 0 | 11 565 | 16 552 | 326 | 4 120 | 27 120 | 25 855 | 12 932 |
| Long-term debt | 0 | 28 | 0 | 0 | 4 526 | 6 549 | 8 388 | 5 | 0 | 0 |
| Short-term debt | 0 | 100 | 3 055 | 33 364 | 106 558 | 91 045 | 74 242 | 31 218 | 10 628 | 529 |
| Total debt | 0 | 128 | 3 055 | 33 364 | 111 083 | 97 594 | 82 630 | 31 223 | 10 628 | 529 |
EBITDA margin
69.8%
This company
15.8%
Market median
+342% vs market
20152024
Equity ratio
96.1%
This company
38.2%
Market median
+152% vs market
20152024
Return on equity
54.7%
This company
18.4%
Market median
+197% vs market
20152024
Net profit margin
66.7%
This company
8.1%
Market median
+723% vs market
20152024
Asset turnover
0.79×
This company
1.12×
Market median
-29% vs market
20152024
Debt / equity
0.04×
This company
0.62×
Market median
+94% vs market
20152024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
GO Deputy Member | Deputy Member | 2018 | — | — |
OK Deputy Member | Deputy Member | 2018 | — | — |
IR Deputy Member | Deputy Member | 2018 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2018 | — | — | |
| Chairman | 2018 | — | — | |
| Board of Directors | 2018 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Norvet As | Company | 80.0% | 80.0% | 2024 |
Åkerøya As | Company | 20.0% | 20.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Berfjord Invest As
SALMO PHARMA AS Board members of SALMO PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Geir Ove Aaker | Deputy Member | 0 companies |
| Olav Kyrre Rikhardsen | Deputy Member | 0 companies |
| Ingebjørg Rikhardsen | Deputy Member | 0 companies |
| Jonny Berfjord | Board of Directors | 0 companies |
| Bjørn-Inge Rikhardsen | Chairman | 0 companies |
| Berit Anne Aas Rikhardsen | Board of Directors | 0 companies |